Castle Biosciences Inc. (CSTL) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, CSTL scores 63 / 100, letter grade C, with the verdict "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are: Fundamental Cash Engine 13 / 20 (ROIC -9.3%; FCF yield 2.41%); Whale 13F Flow 16 / 20 (institutional accumulation and options positioning); Insider Conviction 7 / 20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 13 / 20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet 14 / 20 (Altman Z 6.97; Piotroski F 6/9; Debt/Equity 0.02). For a prospective investor, the strongest pillar is institutional positioning, while the weakest is insider conviction, which the rating scores at 7 of 20. The negative ROIC and the 2.41% FCF yield indicate that the cash-generation case is modest rather than compelling. The balance-sheet pillar offers the most support, given the low leverage and the forensic scores reported. Taken together, the rating frames CSTL as a balanced risk-reward profile rather than a clear upside or downside setup, so the upside drivers are the institutional and balance-sheet strengths, and the valuation tradeoff is weak operating profitability against a share price that has moved sharply within its 52-week range.

Castle Biosciences Inc. (CSTL) is a NASDAQ-listed issuer in the Health Care sector and Medical Specialities industry, per the company profile. The source data does not describe its products, customers, or revenue model beyond the sector and industry classification. Per the SEC financials, the company reported FY 2025 revenue of $344.2M and a gross margin of 79.4% per the market data section. The source data does not identify specific products or customer segments.

Per the SEC financials, revenue grew from $219.8M in FY 2023 to $344.2M in FY 2025, but operating income moved from positive in FY 2024 to $-42.8M in FY 2025. The market data reports an operating margin of -12.4%, a net margin of -7%, and ROIC of -9.3%. The forensic balance sheet pillar cites an Altman Z-Score of 6.97 and a Piotroski F-Score of 6/9, alongside a Debt/Equity ratio of 0.02. Reported cash of $116.7M against debt of $9.6M reflects low leverage in FY 2025.

Per the recent news section, the catalysts are largely market-wire items. A headline states that Castle Biosciences will participate in upcoming investor conferences. Multiple items report insider selling by the Chief Commercial Officer, including a sale of 3,288 shares and a proposal to sell 13,154 shares, and one headline describes the stock price declining 6.1% following insider selling. A TradingView item cites a Q3'26 revenue estimate of 92.41M USD. The item flagged as RISK WATCH is a Simply Wall St report noting the stock dropped. The Butterfly Supply-Chain Graph lists no supply-chain links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply-chain classification is NONE, with no butterfly links and no proprietary signals. The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations. Watch items grounded in the source data are the recurring insider-selling headlines, which bear on the insider conviction pillar, and the reported Q3'26 revenue estimate, which the source data does not connect to any supply-chain driver.

• What are the company's specific products, customers, and revenue drivers, given that the source data gives only sector and industry classification?
• What drove the move from negative operating income in FY 2025 to a positive operating result in FY 2024, and what is the path back to profitability?
• Why are EPS, P/E, forward P/E, and EV/EBITDA unavailable, and how does the valuation compare to peers?
• What is the size and pattern of the insider-selling activity referenced in the news, and how does it reconcile with the insider conviction score of 7 / 20?
• What is the FY 2026 financial trajectory, given that the only forward datapoint is a Q3'26 revenue estimate without corresponding profit estimates?